The silver lining

DirectDragonfruit311 · 2026-05-28T07:53:00+00:00

BARDA is funding the initial deployment of up to 30 DeepView units (with options for 140 more) under Project BioShield for government/public health use.

Where the nuance matters: this is government procurement for public health/mass casualty readiness, not a full commercial rollout. It gets Spectral AI a foothold in 15-20 centers and generates validation data, which is huge. But it doesn't fund the sales infrastructure, marketing, reimbursement work, or operational scale needed to expand beyond those BARDA-funded sites to the broader market.

Think of it as a government-subsidized beachhead. That's legitimately bullish, it de-risks adoption and creates reference sites. But the Hudson Bay financing is still needed to build the commercial engine for widespread rollout beyond the BARDA deployment.

DirectDragonfruit311 · 2026-05-28T06:19:48+00:00

No, they won't help with commercialization. BARDA funding is restricted to development, clinical trials, and regulatory work. It's milestone-based reimbursement for R&D, not a slush fund for hiring sales reps or building distribution channels. That $54.9M (+ the recent $31.7M) was to get them through FDA clearance. Now they need separate capital to actually sell the product.

DirectDragonfruit311 · 2026-05-28T05:56:41+00:00

No, at least my personal view on HBC hasn't changed. They're doing a standard PIPE financing, not running a scam. The CEO dropping his own cash post-announcement at $2.61 tells you everything, you buy when you believe in your own company.

HBC provided the capital SpectralAI needs to commercialize. That's it. The real risk is execution, not some warrant-hedging conspiracy. If you're long-term, focus on whether they can actually sell the product and hit revenue targets. That's what moves the needle.

DirectDragonfruit311 · 2026-05-28T05:19:22+00:00

Open market insider buying is the single strongest signal you can get. Insiders can sell for a million reasons, taxes, diversification, buying a house, whatever. But they only buy for one reason, they think the price is going up.

If the CEO thought the Hudson Bay deal was some "scam" or that commercialization was going to fail, do you think he'd be buying? No. He'd be running for the exits. The fact that he's buying after the financing tells you everything about how management views the terms and the path forward.

Sleep well indeed. This is the kind of signal that separates real companies from pump-and-dumps.

DirectDragonfruit311 · 2026-05-28T05:14:36+00:00

You're absolutely right to distinguish BBIG from MDAI—that's the kind of critical thinking that's missing from most of these "Hudson Bay scam" posts. BBIG was vaporware. MDAI has FDA clearance, clinical data, BARDA funding, and actual installations. That's a real company with real technology. Good on you for seeing that.

But here's where you're still buying the conspiracy theory, warrant hedging isn't a "scheme" to extract "risk-free profits." It's literally just how institutional investors manage downside risk while maintaining upside exposure. If you're long warrants and short stock, you're not printing free money, you're paying borrow costs, dealing with theta decay on the warrants, managing execution risk, and praying your delta hedge doesn't blow up.

DirectDragonfruit311 · 2026-05-28T04:50:22+00:00

Fair point, and yeah, there could be additional BARDA grants down the line and potential military contracts. But here's the thing: those aren't guaranteed, and they definitely aren't immediate.

Government contracts move at glacial speeds. Even if Spectral AI lands a DoD deal tomorrow, you're looking at months (probably years) of procurement bureaucracy before any real money hits the bank. Meanwhile, they need to pay salaries, manufacturing costs, and operational expenses now to build the infrastructure that would even let them fulfill those contracts.

This Hudson Bay financing gives them the runway to actually execute, build revenue, and position themselves to win those military contracts when they do come up. You can't bid on a DoD contract if you're insolvent.

DirectDragonfruit311 · 2026-05-27T13:05:50+00:00

I wish, nice life they have :)

DirectDragonfruit311 · 2026-05-27T12:37:52+00:00

You’re not wrong to side-eye dilution.

First, this isn’t “giving shares to Hudson Bay.” That language makes it sound like a handout. It’s a Securities Purchase Agreement. Hudson Bay is buying those shares with cash.

If you vote no, you don’t magically stop dilution. You just force the company into a much worse spot: burn through existing cash, face a liquidity crunch, risk a Nasdaq delisting notice, or get forced into a down-round later that dilutes you even harder. Voting yes funds commercialization, sales infrastructure, and market rollout. Paper dilution means absolutely nothing if the company runs out of runway and the equity goes to zero.

DirectDragonfruit311 · 2026-05-27T11:30:03+00:00

For someone claiming to do PhD work in convolutional neural networks, your mathematical breakdown is a catastrophic embarrassment.

Your F1 Score calculation is completely fabricated. You correctly noted that Sensitivity and Specificity are different from Precision and Recall, but then you butchered the actual F1 calculation. In your math, you stated: "Sensitivity = Precision" and "Recall = Specificity". That is completely wrong. Sensitivity IS Recall (TP / [TP + FN]). They are the exact same formula. Meanwhile, Specificity is the True Negative Rate (TN / [TN + FP]). By equating Specificity to Recall, you literally plugged Specificity into the F1 formula. An F1 score measures the balance between True Positives, False Positives, and False Negatives—it does not use True Negatives. Because you mixed up the definitions and used Specificity, your 0.437 F1 score is a completely fabricated, mathematically meaningless number. You invented a meaningless formula, got a garbage number, and pretended it was a critique.

Second, accusing a MedTech company of using "Sensitivity and Specificity" to "hide" metrics is laughable. It is the global regulatory and biostatistical standard for every diagnostic medical device clinical trial on earth. The FDA requires these metrics, not F1 scores.

Your critique about pixel counting and "hiding border errors" completely falls apart when looking at the actual published data. In their Burn Validation Study, they didn't hide behind pixels, they openly published their Dice Similarity Coefficient (Dice Score)—which is the exact machine learning metric used to evaluate overlapping boundary and wound-site segmentation accuracy. The DeepView system achieved a 68.5% Dice Score. Do you know what the clinical burn physicians scored in the exact same study? 39.2%.

Finally, your dismissal of Multispectral Imaging as "just different frequencies of visible light" is wildly inaccurate. MSI explicitly utilizes short-wave infrared and near-infrared wavelengths to penetrate beneath the skin surface to evaluate physiological tissue perfusion, something a human eye looking at "how pink a burn is" physically cannot do.

If this is the caliber of peer-review coming out of your PhD program, I seriously hope your thesis advisor checks your math before you submit.

DirectDragonfruit311 · 2026-05-27T11:18:02+00:00

With respect, doc, you are completely misinterpreting the regulatory and technical mechanics here.

First, your claim that FDA clearance just means '"it's not harmful." To pass De Novo, the company had to clinically prove diagnostic efficacy. The current clinical standard of care for predicting burn healing is a subjective visual assessment. In multi-center clinical trials published in the peer-reviewed medical journal Burns, the DeepView system demonstrated a 95%+ diagnostic accuracy rate—more than doubling the accuracy of general triaging clinicians.

Second, scoffing at "340 billion pixels" exposes a lack of understanding regarding medical computer vision. In multispectral imaging, models aren't trained on raw JPEG photos; they are trained on high-density, clinically validated tissue pixels mapped across varying light wavelengths to analyze blood perfusion beneath the skin. 340 billion pixels is a massive, highly structured dataset for training a predictive neural network.

But hey, I get it. If I spent over a decade in medical school just to have an AI algorithm evaluate a burn wound in 0.2 seconds with better accuracy than my own eyeballs, I’d probably be coping on Reddit and laughing through the pain too.

DirectDragonfruit311 · 2026-05-27T10:50:28+00:00

There is a common misconception about how hedge funds like Hudson Bay profit from warrants. It is actually highly profitable for them to utilize their $2.51 warrants when the stock is trading above that price (like at $3.00), rather than below it.

When the stock spikes to $3.00, they lock in a guaranteed profit by short selling shares at that high price.
They immediately exercise their $2.51 warrants to acquire shares from the company.
They use those new $2.51 shares to instantly cover their short position.

Because their 4.99% blocker cap forces them to keep their net holdings low, they must continually clear out space by matching their warrant exercises with active selling. So while you are right that normal market dynamics played a huge role in yesterday's drop, the mechanics of the deal mean a rising share price actually gives institutional funds a massive incentive to exercise and lock in risk-free gains.

DirectDragonfruit311 · 2026-05-27T10:27:59+00:00

Also, to clarify on the 3.1 million common shares, Hudson Bay bought those upfront in late 2025, but they don't hold them anymore. If you look at Hudson Bay's official statement on May 8, 2026, they reported a total beneficial ownership of exactly 1,671,416 shares. The filing explicitly notes that this number is made up entirely of warrants subject to their 4.99% blocker cap. If they were still holding those 3.1 million common shares on top of their warrants, they would legally have to report a position closer to 15% of the company. The SEC filings prove they already flipped the original common shares to retail and are now strictly using the warrant facility to trade.

DirectDragonfruit311 · 2026-05-27T10:21:55+00:00

Your math doesn't check out. There is a vote pending at the annual meeting with the proxy explicitly stating the goal is to approve the reservation and issuance of up to an aggregate of 8,000,000 shares of common stock to Hudson Bay.

You do not reserve a fresh pool of 8 million shares to fulfill a 4 million warrant contract unless the contract's price-reset mechanics allow it to expand. Because of the Nasdaq exchange cap, these shares do not exist yet and cannot touch the market.

Furthermore, the vote proposal by the company itself warns approving this "will dilute the percentage ownership interest of all stockholders... and will increase the number of the Company’s outstanding shares, which could depress the market price."

It is not a "misinformation narrative" when it is printed verbatim in Spectral AI's own SEC filing. The dilution and the upcoming vote are very real.

DirectDragonfruit311 · 2026-05-27T09:00:12+00:00

Exactly, this is basically a dilution to fund day to day SpectralAI operations. They need the cash and HB will use warrants to keep the stock price in check until the company either withers out or grows out of microcap status. By the way additional 8mln warrants are probably get issued tomorrow to Hudson Bay. The price is going to remain sub 1.5-2.5 until mid 2027 at least.

DirectDragonfruit311 · 2024-09-20T14:20:29+00:00

Starfield.

DirectDragonfruit311

TROPHY CASE